Rabbit Anti-Human PTK2 Polyclonal Antibody

NuMA, a nuclear protein that associates with the mitotic apparatus, was identified in 1980 as a high molecular weight component of the nuclear matrix with the unusual property of associating with the microtubules of the spindle apparatus during mitosis. Over the past two years, a burst of interest in this intriguing protein has led to the clear documentation of its cell cycle redistribution, determination of its primary sequence, elucidation of its cell cycle dependent targeting domains, as well as disruption of its function through antibody microinjection and expression of dominant-negative mutants. Together, these data support a central role for NuMA in both mitotic-spindle dynamics and the reformation of the daughter cell nuclei at the end of mitosis.

Background Patients with severe acute pancreatitis (SAP), which is characterized by high morbidity and mortality, account for an increasing medical burden worldwide. We previously found that mesenchymal stem cells (MSCs) could attenuate SAP and that expression of long noncoding RNA H19 (LncRNA H19) was upregulated in rats receiving MSCs. In the present study, we investigated the mechanisms of LncRNA H19 regulating the therapeutic efficacy of MSCs in the alleviation of SAP. Methods MSCs transfected with LncRNA H19 overexpression and knockdown plasmids were intravenously injected into rats 12 h after sodium taurocholate (NaT) administration to induce SAP. Results Overexpressing LncRNA H19 in MSCs significantly enhanced the anti-inflammatory capacity of the MSCs, inhibited autophagy via promotion of focal adhesion kinase (FAK)-associated pathways, and facilitated cell proliferation by increasing the level of beta-catenin in rats with SAP. LncRNA H19 functioned as a competing endogenous RNA by sponging miR-138-5p and miR-141-3p. Knocking down miR-138-5p in MSCs increased the expression of protein tyrosine kinase 2 (PTK2, encoding FAK) to suppress autophagy, while downregulating miR-141-3p enhanced the level of beta-catenin to promote cell proliferation. Conclusions In conclusion, LncRNA H19 effectively increased the therapeutic efficacy of MSCs in rats with SAP via the miR-138-5p/PTK2/FAK and miR-141-3p/beta-catenin pathways.